A Phase 2 interventional study of PF-07817883 and Placebo in SARS-CoV-2 Infection, sponsored by Pfizer. Completed at 53 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2024-10-09.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in COVID-19 by Pfizer — 4 open to participants now, 10 under way, 3 of them phase 3. COVID-19 · Pfizer.
Among the 69 studies in COVID-19 by Pfizer, this one is the 11th largest by enrollment of the 41 interventional ones that give a count, is one of 12 that started in 2023, is one of 7 in phase 2, and was the 38th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →4 of the 69 studies in COVID-19 by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Argentina, Belgium and 15 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, Belgium and 16 more countries
Ages 12+
Pfizer · Sites in Korea, Republic of
Ages 19+
Pfizer · Sites in United States, Bulgaria, Japan and 4 more countries
Ages 0–17
By country, each count listing its studies:
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 11 · Phase 3 8 · Phase 4 1
First in 2020; this study’s year is marked. 12 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 240 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 20 across the 41 interventional studies, 2,038 across the 28 observational. Of the 53 that completed or were terminated, 39 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
5 of the studies in COVID-19 by Pfizer that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT06613984PfizerKorean Post Marketing Surveillance for Comirnaty Injection (Bretovameran) | 2026-12-30 |
| NCT05032976PfizerKorea Comirnaty Post-marketing Surveillance | 2027-01-24 |
| NCT05160636PfizerA Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza | 2027-01-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 69 studies in COVID-19 by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to understand the effects and safety of PF-07817883 treatment. The study wants to know how PF-07817883 treatment lowers the level of the virus that causes COVID 19. To understand that samples are collected from adult participants who have the symptoms of COVID 19 but are not hospitalized.
The study is seeking for participants who:
Around 228 participants with a confirmed case of COVID 19 are planned to be taken into the study. Participants will be randomly grouped to receive PF-07817883. Three groups will receive 100, 300, 600mg of PF-07817883 and one of the groups will receive placebo (a pill that doesn't have any medicines) orally every 12 hours for 5 days.
The study is going to last up to 5 weeks. This includes the initial period of selecting participants, participants receiving the medicine or the placebo and then a 4-week follow-up period after giving the participants the last medicine.
The study team will monitor how each participant is doing with the study treatment during the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants ≥18 to \<65 years of age at the time of the Screening Visit.
Exclusion Criteria:
with ≥1 of the following:
Use of at least 1 of the following immune-weakening medications:
iii. Has received equivalent to prednisone ≥20 mg daily for at least 14 consecutive days within 30 days prior to study entry.
iv. Active treatment causing significant immunosuppression, including alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents, TNF blockers, or other highly immunosuppressive drugs such as biologics.
Known history of any of the following abnormalities in clinical laboratory tests (within past 6 months of the screening visit):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: PF-07817883
Drug: PF-07817883
Drug: PF-07817883
Drug: Placebo
Arm 1: low dose Arm 2: medium dose Arm 3: high dose
Placebo
Change From Baseline in Logarithm Base 10 (Log10) Transformed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Ribo Nucleic Acid (RNA) Level on Day 5
Change from baseline in SARS-CoV-2 RNA level at Day 5 was analyzed using Mixed Effects Repeated Measures (MMRM) model with fixed effects including treatment, visit, visit by treatment interaction, and baseline viral load. Covariates included days from baseline since symptom onset (\<=3 versus \[vs.\] \>3 days), vaccination status (complete or partial vs. unvaccinated), baseline anti-N serology status and age at screening (years). Participants were excluded from the analysis if baseline viral load was less than 4\*log10 copies/milliliter, missing, or not detected.
Time frame: Baseline (Day 1), Day 5
Change From Baseline in Log10 Transformed SARS-CoV-2 RNA Level on Days 3, 10 and 14
Change from baseline in SARS-CoV-2 RNA level at Day 3, Day 10 and Day 14 were analyzed using MMRM model with fixed effects including treatment, visit, visit by treatment interaction, and baseline viral load. Covariates included days from baseline since symptom onset (\<=3 vs. \>3 days), vaccination status (complete or partial vs. unvaccinated), baseline anti-N serology status and age at screening (years). Participants were excluded from the analysis if baseline viral load was less than 4\*log10 copies/milliliter, missing, or not detected.
Time frame: Baseline (Day 1), Day 3, Day 10 and Day 14
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a study participant after administration of a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. An adverse event is considered a treatment-emergent adverse event (TEAE) if the event started on or after the study medication start date and time. An SAE was any untoward medical occurrence at any dose that: resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions) or resulted in congenital anomaly/birth defect or was considered an important medical event.
Time frame: From start of study intervention up to 28 days after last dose of study intervention (up to 33 days)
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuations
An AE was any untoward medical occurrence in a study participant after administration of a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. An adverse event is considered a treatment-emergent adverse event (TEAE) if the event started on or after the study medication start date and time. Participants with an AE record indicating the AE caused permanent discontinuation from the study were reported under discontinuations from study due to TEAEs. Permanent discontinuations from study intervention due to TEAEs included those participants who had an AE record that indicated that action taken with study treatment was drug withdrawn but AE did not cause the participant to be discontinued from study.
Time frame: From start of study intervention up to 28 days after last dose of study intervention (up to 33 days)
Number of Participants With Laboratory Test Abnormalities
The following laboratory parameters were assessed according to pre-specified criteria for abnormalities: a) hematology; hemoglobin (gram per deciliter \[g/dL\]), (less than\[\<\]0.8\*lower limit of normal \[LLN\]), erythrocytes(10\^12/Liter \[L\])(\< 0.8\*LLN), lymphocytes(10\^9/L)(more than\[\>\]1.2\*upper limit of normal \[ULN\]), neutrophils(\> 1.2\*ULN and \< 0.8\*LLN), basophils(10\^9/L)(\> 1.2\*ULN) and eosinophils (10\^9/L)(\> 1.2\*ULN). b) clinical chemistry; bilirubin(mg/dL)(\> 1.5\*ULN), urea nitrogen(mg/dL)(\> 1.3\*ULN), creatinine(mg/dL)(\> 1.3\*ULN), potassium(milli equivalence per millilitre \[mEq/L\], (\< 0.9\*LLN and \> 1.1\*ULN), calcium (mg/dL)(\< 0.9\*LLN), bicarbonate(mEq/L)(\< 0.9\*LLN and \> 1.1\*ULN), glucose (mg/dL)(\> 1.5\*ULN), creatine kinase(units per litre \[U/L) (\> 2.0\* ULN), D-Dimer(nanogram per milliliter\[ng/mL\]), (\>1.5\*ULN) and c)urinalysis; bacteria (low power field \[LPF\]\>20). Number of participants with any laboratory abnormalities meeting pre-specified criteria are reported in this outcome measure.
Time frame: From start of study intervention up to 28 days after last dose of study intervention (up to 33 days).
Number of Participants Meeting Pre-defined Criteria of Vital Sign Abnormalities
Vital signs included blood pressure and pulse rate and were assessed with the participant in the supine or seated position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Pre-defined criteria for vital sign abnormalities was as systolic blood pressure (millimeter of mercury \[mmHg\]): value \< 90, change \>= 30 increase and change \>= 30 decrease, diastolic blood pressure (mmHg): value \<50; change \>= 20 increase and change \>= 20 decrease, pulse rate (beats per minute \[bpm\]): value \< 40 and value \> 120.
Time frame: From start of study intervention up to 28 days after last dose of study intervention (up to 33 days).
Number of Participants Meeting Pre-defined Criteria For ECG Abnormalities
Twelve lead ECGs were collected using an ECG machine that automatically calculated heart rate and measured PR interval, QT interval, and QT interval correct by Frederica formula (QTcF). ECG abnormalities included: PR interval (millisecond \[msec\]): value \>=280, change \>40 increase; QT interval aggregate (msec): value \> 500), QTcF interval (450 \< value =\< 480; 480 \< value =\< 500; value \> 500; 30 \< change \<= 60 increase and change \> 60 increase).
Time frame: From baseline (Day 1) up to Day 10
| Milestone | PF-07817883 100mg | PF-07817883 300mg | PF-07817883 600mg | Placebo |
|---|---|---|---|---|
| Started | 40 | 40 | 80 | 80 |
| Treated | 40 | 39 | 79 | 79 |
| Completed | 39 | 36 | 77 | 75 |
| Not completed | 1 | 4 | 3 | 5 |
| Withdrew: Adverse event | 0 | 1 | 1 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 1 | 3 |
| Withdrew: Randomized not treated | 0 | 1 | 1 | 1 |
| Milestone | PF-07817883 100mg | PF-07817883 300mg | PF-07817883 600mg | Placebo |
|---|---|---|---|---|
| Started | 39 | 37 | 78 | 76 |
| Completed | 39 | 37 | 77 | 76 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
Change from baseline in SARS-CoV-2 RNA level at Day 5 was analyzed using Mixed Effects Repeated Measures (MMRM) model with fixed effects including treatment, visit, visit by treatment interaction, and baseline viral load. Covariates included days from baseline since symptom onset (\<=3 versus \[vs.\] \>3 days), vaccination status (complete or partial vs. unvaccinated), baseline anti-N serology status and age at screening (years). Participants were excluded from the analysis if baseline viral load was less than 4\*log10 copies/milliliter, missing, or not detected.
| Log10 copies/milliliter | PF-07817883 100mg | PF-07817883 300mg | PF-07817883 600mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Logarithm Base 10 (Log10) Transformed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Ribo Nucleic Acid (RNA) Level on Day 5 | -3.883 (-4.247 to -3.520) | -4.015 (-4.452 to -3.578) | -4.380 (-4.671 to -4.088) | -3.213 (-3.517 to -2.908) |
Change from baseline in SARS-CoV-2 RNA level at Day 3, Day 10 and Day 14 were analyzed using MMRM model with fixed effects including treatment, visit, visit by treatment interaction, and baseline viral load. Covariates included days from baseline since symptom onset (\<=3 vs. \>3 days), vaccination status (complete or partial vs. unvaccinated), baseline anti-N serology status and age at screening (years). Participants were excluded from the analysis if baseline viral load was less than 4\*log10 copies/milliliter, missing, or not detected.
| Log10 copies/milliliter | PF-07817883 100mg | PF-07817883 300mg | PF-07817883 600mg | Placebo |
|---|---|---|---|---|
| Day 3 | -2.006 (-2.371 to -1.641) | -2.702 (-3.123 to -2.280) | -2.546 (-2.818 to -2.274) | -1.398 (-1.684 to -1.112) |
| Day 10 | -5.027 (-5.326 to -4.728) | -5.085 (-5.423 to -4.748) | -5.305 (-5.529 to -5.082) | -5.091 (-5.332 to -4.851) |
| Day 14 | -5.682 (-5.913 to -5.451) | -5.500 (-5.769 to -5.231) | -5.826 (-6.009 to -5.643) | -5.443 (-5.637 to -5.250) |
An AE was any untoward medical occurrence in a study participant after administration of a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. An adverse event is considered a treatment-emergent adverse event (TEAE) if the event started on or after the study medication start date and time. An SAE was any untoward medical occurrence at any dose that: resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions) or resulted in congenital anomaly/birth defect or was considered an important medical event.
| Participants | PF-07817883 100mg | PF-07817883 300mg | PF-07817883 600mg | Placebo |
|---|---|---|---|---|
| TEAEs | 2 | 5 | 11 | 9 |
| SAEs | 0 | 1 | 0 | 0 |
An AE was any untoward medical occurrence in a study participant after administration of a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. An adverse event is considered a treatment-emergent adverse event (TEAE) if the event started on or after the study medication start date and time. Participants with an AE record indicating the AE caused permanent discontinuation from the study were reported under discontinuations from study due to TEAEs. Permanent discontinuations from study intervention due to TEAEs included those participants who had an AE record that indicated that action taken with study treatment was drug withdrawn but AE did not cause the participant to be discontinued from study.
| Participants | PF-07817883 100mg | PF-07817883 300mg | PF-07817883 600mg | Placebo |
|---|---|---|---|---|
| Discontinuations from study due to TEAEs | 0 | 1 | 0 | 0 |
| Permanent discontinuations from study intervention due to TEAEs | 0 | 0 | 1 | 0 |
The following laboratory parameters were assessed according to pre-specified criteria for abnormalities: a) hematology; hemoglobin (gram per deciliter \[g/dL\]), (less than\[\<\]0.8\*lower limit of normal \[LLN\]), erythrocytes(10\^12/Liter \[L\])(\< 0.8\*LLN), lymphocytes(10\^9/L)(more than\[\>\]1.2\*upper limit of normal \[ULN\]), neutrophils(\> 1.2\*ULN and \< 0.8\*LLN), basophils(10\^9/L)(\> 1.2\*ULN) and eosinophils (10\^9/L)(\> 1.2\*ULN). b) clinical chemistry; bilirubin(mg/dL)(\> 1.5\*ULN), urea nitrogen(mg/dL)(\> 1.3\*ULN), creatinine(mg/dL)(\> 1.3\*ULN), potassium(milli equivalence per millilitre \[mEq/L\], (\< 0.9\*LLN and \> 1.1\*ULN), calcium (mg/dL)(\< 0.9\*LLN), bicarbonate(mEq/L)(\< 0.9\*LLN and \> 1.1\*ULN), glucose (mg/dL)(\> 1.5\*ULN), creatine kinase(units per litre \[U/L) (\> 2.0\* ULN), D-Dimer(nanogram per milliliter\[ng/mL\]), (\>1.5\*ULN) and c)urinalysis; bacteria (low power field \[LPF\]\>20). Number of participants with any laboratory abnormalities meeting pre-specified criteria are reported in this outcome measure.
| Participants | PF-07817883 100mg | PF-07817883 300mg | PF-07817883 600mg | Placebo |
|---|---|---|---|---|
| Number of Participants With Laboratory Test Abnormalities | 4 | 4 | 18 | 13 |
Vital signs included blood pressure and pulse rate and were assessed with the participant in the supine or seated position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Pre-defined criteria for vital sign abnormalities was as systolic blood pressure (millimeter of mercury \[mmHg\]): value \< 90, change \>= 30 increase and change \>= 30 decrease, diastolic blood pressure (mmHg): value \<50; change \>= 20 increase and change \>= 20 decrease, pulse rate (beats per minute \[bpm\]): value \< 40 and value \> 120.
| Participants | PF-07817883 100mg | PF-07817883 300mg | PF-07817883 600mg | Placebo |
|---|---|---|---|---|
| Systolic blood pressure; value < 90 (mmHg) | 0 | 0 | 1 | 1 |
| Systolic blood pressure; change >= 30 (mmHg) increase | 0 | 0 | 1 | 0 |
| Systolic blood pressure; change >= 30 (mmHg) decrease | 1 | 2 | 0 | 3 |
| Diastolic blood pressure; value <50 (mmHg) | 0 | 0 | 0 | 0 |
| Diastolic blood pressure; change >= 20 (mmHg) increase | 1 | 1 | 1 | 2 |
| Diastolic blood pressure; change >= 20 (mmHg) decrease | 0 | 0 | 2 | 2 |
| Pulse rate; value < 40 (bpm) | 0 | 0 | 0 | 0 |
| Pulse rate; value > 120 (bpm) | 0 | 0 | 0 | 0 |
Twelve lead ECGs were collected using an ECG machine that automatically calculated heart rate and measured PR interval, QT interval, and QT interval correct by Frederica formula (QTcF). ECG abnormalities included: PR interval (millisecond \[msec\]): value \>=280, change \>40 increase; QT interval aggregate (msec): value \> 500), QTcF interval (450 \< value =\< 480; 480 \< value =\< 500; value \> 500; 30 \< change \<= 60 increase and change \> 60 increase).
| Participants | PF-07817883 100mg | PF-07817883 300mg | PF-07817883 600mg | Placebo |
|---|---|---|---|---|
| PR Interval, value >= 280 (msec) | 0 | 0 | 0 | 0 |
| PR Interval, change > 40 increase (msec) | 0 | 2 | 1 | 0 |
| QT Interval (msec) value >500 | 0 | 0 | 0 | 0 |
| QTcF Interval, 450 < value =< 480 (msec) | 1 | 1 | 2 | 6 |
| QTCF Interval, 480 < value =< 500 (msec) | 0 | 0 | 0 | 0 |
| QTCF Interval, value > 500 (msec) | 0 | 0 | 0 | 0 |
| QTCF Interval, 30 < change <= 60 increase (msec) | 5 | 6 | 6 | 9 |
| QTCF Interval, change > 60 increase (msec) | 0 | 0 | 0 | 0 |
Collected over From start of study intervention up to 28 days after last dose of study intervention (up to 33 days).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PF-07817883 100mg | 0/40 (0%) | 0/40 (0%) | 0/40 (0%) |
| PF-07817883 300mg | 0/39 (0%) | 1/39 (2.6%) | 1/39 (2.6%) |
| PF-07817883 600mg | 0/79 (0%) | 0/79 (0%) | 2/79 (2.5%) |
| Placebo | 0/79 (0%) | 0/79 (0%) | 4/79 (5.1%) |
| Event | PF-07817883 100mg | PF-07817883 300mg | PF-07817883 600mg | Placebo |
|---|---|---|---|---|
| Supraventricular extrasystolesCardiac disorders | 0/40 | 1/39 | 0/79 | 0/79 |
| Event | PF-07817883 100mg | PF-07817883 300mg | PF-07817883 600mg | Placebo |
|---|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 0/40 | 1/39 | 2/79 | 4/79 |
The full analysis set (FAS) included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention Participants were analyzed according to the intervention they were actually randomized.
| Age, Continuous(Years) | PF-07817883 100mg | PF-07817883 300mg | PF-07817883 600mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 43.6 ± 12.30 | 41.9 ± 11.31 | 41.4 ± 11.60 | 41.5 ± 12.97 | 41.9 ± 12.10 |
| Sex: Female, Male(Participants) | PF-07817883 100mg | PF-07817883 300mg | PF-07817883 600mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 23 | 29 | 50 | 45 | 147 |
| Male | 17 | 10 | 29 | 34 | 90 |
| Ethnicity (NIH/OMB)(Participants) | PF-07817883 100mg | PF-07817883 300mg | PF-07817883 600mg | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 35 | 31 | 63 | 64 | 193 |
| Not Hispanic or Latino | 5 | 8 | 15 | 15 | 43 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | PF-07817883 100mg | PF-07817883 300mg | PF-07817883 600mg | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 2 | 6 | 2 | 11 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 12 | 6 | 20 |
| White | 39 | 35 | 60 | 69 | 203 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 1 | 2 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from May 2023 to primary completion in Sep 2023, 3 months.
Results were first posted in Oct 2024, 1 year after primary completion.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 3 months is below that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibuzatrelvir